The Progeria Research Foundation is ranked among medical research organizations in Peabody, MA, with an America's Best Score of 83 out of 100, based on its 2025 Form 990.
Discover treatments & cure for progeria & its aging related disorders, including heart disease.
Largest programs · fiscal year 2025
Progeria drug trial: The Progeria Research Foundation and boston children's hospital continue their partnership for conducting clinical drug trials for children with progeria. The clinical trial team: A team of professionals at boston children's hospital and brigham & women's hospital working with children with progeria from around the globe.$927,130 spent · 30.7% of program spending
Future trial efforts: Prf engages members in the scientific community with expertise in various drugs and/or genetic therapies for the treatment and potential cure for progeria. The investigation and collaborative evaluation of drug therapies is pursued to identify drug candidates/genetic therapies that can lead to future clinical trials.$574,601 spent · 19.0% of program spending
Diagnostic testing: Prf developed a diagnostic test for progeria in the wake of the 2003 gene discovery so those with progeria, their families and medical caretakers can for the first time be given a definitive scientific diagnosis. This can translate into earlier diagnosis, fewer misdiagnoses and early medical intervention to ensure a better quality of life for those with progeria.(see schedule o… Read more
Diagnostic testing: Prf developed a diagnostic test for progeria in the wake of the 2003 gene discovery so those with progeria, their families and medical caretakers can for the first time be given a definitive scientific diagnosis. This can translate into earlier diagnosis, fewer misdiagnoses and early medical intervention to ensure a better quality of life for those with progeria.(see schedule o for continuation)medical & research database: The database is a collection of medical records of progeria patients from all over the world. The data is rigorously analyzed to determine the best course of treatments to improve the patients' quality of life. This information is invaluable for the attending physician to guide the family through the best course of action. Database material was used to create prf's comprehensive healthcare recommendations handbook on progeria aimed at optimizing quality of life. The database was also critical in determining the primary clinical outcome parameter for past progeria clinical drug trials.prf translation program: In touch with the world. With a prominent global outreach, prf eliminates barriers of communication for patients and their families around the world. This initiative has succeeded in translating prf program and medical care materials into over 3 dozen different languages.the progeria handbook: A guide for families and health care providers of children and young adults with progeria that includes daily care recommendations and extensive treatment guidelines. It is published in English and several other languages to allow its use throughout the world.international progeria registry: Consists of centralized contact and other information on children and families living with progeria. The registry provides data on patient demographics and assures rapid distribution of any new information that may benefit those with progeria.scientific conferences; prf organizes meetings that bring together scientists and clinicians from all over the world to share their expertise and cutting edge scientific data, and foster collaboration in the fight against progeria and other aging related conditions.clinical trials: In 2025, 7 children and young adults came to boston to undergo testing and obtain lonafarnib for the prolon 3 (lonafarnib extension) trial, which allows children and young adults who are unable to obtain lonafarnib in their home country to receive this life extending treatment through this trial, while also gathering important disease-related data. In 2025, the team continues to gather data from the ongoing clinical drug trial. In addition, prf collaborated with prg science & technology in a trial involving the drug progerinin. Ten children and young adults came to boston three times in 2025 to participate in the trial. One of the 10 participants one also participated in the prolon 3 trial simultaneously during one of the visits.
$1,522,985 spent · 50.4% of program spending
Where each dollar went · fiscal year 2025
Of every dollar it spent, 73¢ went to programs, 22¢ to management and 5¢ to fundraising.
Programs $3,024,716
Management $930,856
Fundraising $208,071
In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.
Spending on programs Not scored; America's Best needs 65%+
73%
Meets
Tax filings by year
Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.
Revenue$4,458,016Fiscal year 2025
Expenses$4,163,643Fiscal year 2025
Total assets$49,979,002Fiscal year 2025
Total liabilities$526,805Fiscal year 2025
Fiscal year ending December2025
Revenue$4,458,016
Expenses$4,163,643
Net income$294,373
Net assets$49,452,197
Notable sources of revenue
Percent of total revenue
Contributions
$2,020,617
45.3%
Program services
$0
0.0%
Investment income
$2,433,984
54.6%
Other (net)
$3,415
0.1%
Assets / debt
Total assets
$49,979,002
Total liabilities
$526,805
Net assets
$49,452,197
Compensation
Not in our extract for this year.
Fiscal year ending December2024
Revenue$3,650,308
Expenses$5,902,368
Net income−$2,252,060
Net assets$47,400,671
Notable sources of revenue
Percent of total revenue
Contributions
$1,862,392
51.0%
Program services
$0
0.0%
Investment income
$1,752,842
48.0%
Other (net)
$35,074
1.0%
Assets / debt
Total assets
$48,028,500
Total liabilities
$627,829
Net assets
$47,400,671
Compensation
Not in our extract for this year.
Fiscal year ending December2023
Revenue$2,231,500
Expenses$3,929,965
Net income−$1,698,465
Net assets$48,251,166
Notable sources of revenue
Percent of total revenue
Contributions
$1,555,410
69.7%
Program services
$0
0.0%
Investment income
$668,402
30.0%
Other (net)
$7,688
0.3%
Assets / debt
Total assets
$48,844,685
Total liabilities
$593,519
Net assets
$48,251,166
Compensation
Not in our extract for this year.
Fiscal year ending December2022
Revenue$1,793,850
Expenses$3,126,766
Net income−$1,332,916
Net assets$46,824,384
Notable sources of revenue
Percent of total revenue
Contributions
$2,118,542
118.1%
Program services
$0
0.0%
Investment income
$1,032,490
57.6%
Other (net)
−$1,357,182
−75.7%
Assets / debt
Total assets
$47,596,733
Total liabilities
$772,349
Net assets
$46,824,384
Compensation
Officers and key employees
$215,500
Share of expenses
6.9%
About this data
Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?